{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=3",
    "query": {
      "intervention": "Spironolactone (drug)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 105,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Spironolactone+%28drug%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T19:01:43.939Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01867294",
      "title": "Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Dermatologic Complication"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Management of Therapy Complications",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Sunscreen",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-08-31",
      "completion_date": "2014-06-13",
      "has_results": true,
      "last_update_posted_date": "2020-01-09",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 5,
      "location_summary": "Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more",
      "locations": [
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Saint Cloud",
          "state": "Minnesota"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867294"
    },
    {
      "nct_id": "NCT03874338",
      "title": "CLEAR SYNERGY Neutrophil Substudy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neutrophils.Hypersegmented &#X7C; Bld-Ser-Plas",
        "STEMI - ST Elevation Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Colchicine Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "19 Years to 110 Years"
      },
      "enrollment_count": 322,
      "start_date": "2019-03-04",
      "completion_date": "2024-08-09",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03874338"
    },
    {
      "nct_id": "NCT01422759",
      "title": "Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Hyperandrogenemia",
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "7 Years to 18 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2016-12-09",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-27",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422759"
    },
    {
      "nct_id": "NCT01294319",
      "title": "Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cortisol Resistance",
        "Negative Feedback",
        "ACTH",
        "Mineralcorticoid",
        "Glucocorticoid"
      ],
      "interventions": [
        {
          "name": "Mifepristone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Combined",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2011-01-24",
      "completion_date": "2016-08-10",
      "has_results": true,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01294319"
    },
    {
      "nct_id": "NCT00498537",
      "title": "Spironolactone for Reducing Proteinuria in Diabetic Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2003-01",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2008-10-17",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498537"
    },
    {
      "nct_id": "NCT03174288",
      "title": "The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "OTHER"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2015-08",
      "completion_date": "2019-05-22",
      "has_results": false,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03174288"
    },
    {
      "nct_id": "NCT03652623",
      "title": "Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "Gender",
        "Behavior and Behavior Mechanisms"
      ],
      "interventions": [
        {
          "name": "TDF/FTC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hektoen Institute for Medical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "15 Years to 24 Years"
      },
      "enrollment_count": 49,
      "start_date": "2018-07-23",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652623"
    },
    {
      "nct_id": "NCT02429388",
      "title": "High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-05",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-20",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02429388"
    },
    {
      "nct_id": "NCT05995392",
      "title": "The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Topical spironolactone ophthalmic solution, 0.005 mg/cc",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard W Yee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-08",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 1,
      "location_summary": "Bellaire, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05995392"
    },
    {
      "nct_id": "NCT03777319",
      "title": "Spironolactone Versus Prednisolone in DMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Flanigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2018-12-05",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-10-10T19:01:43.939Z",
      "location_count": 4,
      "location_summary": "Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03777319"
    }
  ]
}